slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 75,481-75,510
Pages 3,679
Rows per page 30
Component
75,481-75,510 of 110,355
19
Lion Electric | Investor Presentation Deck | 31 slidesLion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
09
The slide uses a visual gallery of movie/TV posters to demonstrate the depth of the content library.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · Business Model1 hit
14
The slide uses a three-part structure to explain the flywheel of content investment, acquisition, and revenue growth.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
15
The slide highlights Lionsgate's performance relative to major competitors like Warner Bros, Disney, and Universal.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
19
The chart compares historical M&A transaction multiples (LTM EBITDA) for various media companies, with SEAC (Lionsgate) shown as a benchmark.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
25
The chart highlights Lionsgate Studios as the final bar in green, suggesting a valuation gap relative to peers like Netflix and F1.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
27
Includes footnotes explaining the basis of estimates and definitions.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
28
Includes detailed footnotes explaining the nature of adjustments and the use of 'NRE' (Not Reasonably Estimated) for future projections.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
06
Includes a process flow diagram for the test journey and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market1 hit
06
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
08
The table highlights clinical status, mechanism of action, efficacy, safety, and strategic differentiation.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
09
The slide uses a biological process flow to explain the mechanism of action.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The slide presents 11 distinct bar charts summarizing a study on drug efficacy in a mouse model of MASH (Metabolic dysfunction-associated steatohepatitis).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
19
The slide highlights that DA-1726 achieves weight loss through mechanisms other than just food reduction, as evidenced by higher food intake compared to Tirzepatide.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
20
Includes study design, population, and location details.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
03
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a standard pharmaceutical pipeline visualization format.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
Uses a personal narrative (Shay) to humanize the disease progression alongside clinical data.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
08
The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide defines the statistical populations used for the clinical trial results.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
18
The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
The slide uses a human body diagram to categorize ALS symptoms and bar charts to show the reduction in point loss (slower disease progression) for each category.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC score for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit